| 1) defect model of rats was used for in vivo studies. |
| 2) of the literature resulted in 23 relevant studies. |
| 3) es, and extracting data from the selected studies. |
| 4) g criteria to be included for future EPFR studies. |
| 5) th average sample sizes of 716 across all studies. |
| 6) ld serve in effect as phase 0 and phase I studies. |
| 7) tion was not different in non-MA drinking studies. |
| 8) s well as for mechanistic pharmacokinetic studies. |
| 9) approach for quantitative pharmacokinetic studies. |
| 10) uman ROSMAP datasets and mouse microarray studies. |
| 11) in MRI scans from four neurodevelopmental studies. |
| 12) are commonly used in combination in mouse studies. |
| 13) is use aggregate level data from multiple studies. |
| 14) son r or the Hosmer-Lemeshow test in four studies. |
| 15) n generic NMAs that may contain multi-arm studies. |
| 16) eference lists were searched for relevant studies. |
| 17) summarized results of several independent studies. |
| 18) for a total of 69,350 subjects across all studies. |
| 19) were performed in n = 17 (63%) of the studies. |
| 20) re additional evidence from observational studies. |
| 21) oci (pQTL) and CCR2 expression QTL (eQTL) studies. |
| 22) mbers was not highlighted in the included studies. |
| 23) e therefore used for in vitro and in vivo studies. |
| 24) guide the conduct and critique of scoping studies. |
| 25) stematic, biogeographic, and evolutionary studies. |
| 26) measure may not feasibly handle multi-arm studies. |
| 27) ent steps and should be tested in further studies. |
| 28) genome-wide and phenome-wide association studies. |
| 29) m environmental sequencing and ecological studies. |
| 30) nvestment in regional longitudinal cohort studies. |
| 31) kes it difficult to compare results among studies. |
| 32) sociation with RH in contrast to previous studies. |
| 33) hat were not realized in other simulation studies. |
| |